Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Table 1 Baseline characteristics of patients treated with blood-derived DC vaccinations

Patient^a	Age (years)	Gleason score	Prior treatments	Time start ADT to CRPC (mo)	Baseline PSA (ug/l)^b	Baseline LDH (U/l)^b	Baseline ALP (U/l)^b	All disease sites at baseline^c
mDC-01	60	4 + 5	GOS, BIC	55.4	5.8	187	100	Local, LN, bone
mDC-02	67	4 + 4	PLND, GOS	20.7	4.6	152	80	Local, LN
mDC-03	67	3 + 4	PRTX, GOS, BIC	93.9	10	257	61	Local, LN
mDC-04	60	4 + 3	RP, SRTX, PLND, GOS, BIC	21.5	39	147	113	LN, bone
mDC-05	78	3 + 4	RP, SRTX, PLND, SO, BIC	34.7	4.8	211	79	LN
mDC-06	71	4 + 5	BIC + DUT, SO	94.5	40	185	101	Local, LN, bone
mDC-07	72	5 + 5	CRT, PRTX, PLND, GOS, BIC	27.7	260	222	260	LN, bone
pDC-01	72	5 + 5	PRTX, PLND, LEU, BIC	28.5	6.3	181	98	LN
pDC-02	59	4 + 5	PRTX, GOS, BIC, NIL, DUT, ABI + P/D	83.4	3.6	222	102	Local, LN, bone
pDC-03	59	5 + 5	PLND, LEU, BIC	29.0	8.4	176	81	Local, LN, bone
pDC-04	70	3 + 4	RP, SRTX, PLND, BIC, SO	42.3	19	174	88	LN
pDC-05	65	4 + 3	RP, SRTX, LEU, BIC	41.6	2.6	169	138	LN, bone
pDC-06	79	5 + 4	GOS	85.7	5.7	164	95	Local, LN
pDC-07	82	4 + 5	GOS, BIC	91.6	17	201	53	Local, LN, bone
combiDC-01	74	3 + 4	GOS	46.1	38	168	96	Bone
combiDC-02	67	4 + 4	LEU, BIC	27.6	41	172	83	Local, bone
combiDC-03	63	5 + 4	GOS, LEU, BIC	53.9	18	233	79	Local, LN
combiDC-04	73	4 + 3	LEU, BIC, ENZ	39.3	8.7	179	73	Local, bone
combiDC-05	61	4 + 5	GOS, BIC, ENZ	40.5	3.7	205	123	Local, LN, bone
combiDC-06	73	4 + 4	PRTX, GOS, LEU, BIC, ENZ	20.4	11	131	73	LN, bone
combiDC-07	53	4 + 4	DEG, BIC, ABI + P, SO, ARN-509	29.4	120	161	83	LN, bone

ABI + P: abiraterone plus prednisone; ABI + P/D: abiraterone plus prednisone + switch of prednisone to dexamethasone at PSA-progression; ADT: androgen deprivation therapy; ALP: alkaline phosphatase; ARN-509: apalutamide, ClinicalTrials.gov identifier (NCT number): NCT01946204; CRT cryotherapy, BIC bicalutamide, CRPC castration-resistant prostate cancer, DC dendritic cells, DEG degarelix, DUT dutasteride, ENZ enzalutamide, GOS goserelin, LDH lactate dehydrogenase, LEU leuprorelin, LN lymph node, mo months, NIL nilutamide, PLND pelvic lymph node dissection, PRTX primary radiotherapy, PSA prostate-specific antigen, RP radical prostatectomy, SO surgical orchidectomy, SRTX salvage radiotherapy
^avaccination with myeloid DC (patient mDC-01 to mDC-07), plasmacytoid DC (patient pDC-01 to pDC-07) or combined myeloid DC + plasmacytoid DC (patient combiDC-01 to combiDC-07)
^bmeasured prior to apheresis
^cattributed by experienced nuclear medicine specialists and radiologists. Detected at advanced imaging with contrast enhanced ⁶⁸Ga-prostate-specific membrane antigen PET/CT scans, ferumoxtran-10-enhanced MRIs and MRI bones using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria